6505--Radiopharmaceutical - Pylarify(Piflufolastat F18 Injection)

The Department of Veterans Affairs (VA) Veterans Health Administration is seeking to procure Pylarify (Piflufolastat F18 Injection) radiopharmaceutical through a Request for Quote (RFQ) for the Washington DC VA Medical Center. The solicitation, numbered 36C24525Q0134, is an unrestricted procurement under FAR 13.5 seeking brand name or equal radiopharmaceutical products. Contractors must provide an online ordering system compatible with the Nuclear Pharmacy Management System and demonstrate capability to deliver doses to the Nuclear Medicine Section with specific requirements including emergency add-on dose delivery within two hours. The evaluation will be based on best value, with technical and past performance factors weighted more heavily than price. Key deadlines include December 11, 2024, at 10:00 AM EST for submitting questions and December 17, 2024, at 10:00 AM EST for quote submission.

The solicitation covers a one-year performance period from January 1, 2025, to December 31, 2025, with an estimated quantity of 502 doses at 10 mCi each. There are no specific set-aside designations for this procurement, making it open to all qualified vendors. The place of performance is located at 50 Irving Street NW, Washington DC 20422. Prospective contractors must submit product specifications, warranty information, a manufacturer authorization letter, and two VA contract references from the past three years. The pharmaceutical must be an F-18 based product with a half-life of 109 minutes or longer, and delivery must be possible Monday through Friday at scheduled times. While no specific award value is mentioned, the procurement is for a critical medical imaging radiopharmaceutical used in diagnostic procedures.